Ovarian Cancer

NanoMate System may be used in new diagnostic

Published in Cancer Weekly, June 10th, 2003

Correlogic Systems, Inc., the developer of promising new cancer detection tests that use just a single drop of blood from a patient, has entered into an agreement with Advion BioSciences to explore the use of Advion's NanoMate System as a component of Correlogic's upcoming ovarian cancer clinical trials.

Correlogic's test, called Proteome Pattern Blood Test, scans a drop of blood for protein patterns generated by a mass spectrometer. In February 2002, Correlogic Systems earned international recognition when its joint research with the National Cancer Institute (NCI) and the U.S. Food and Drug Administration (FDA) revealed that the Correlogic test successfully detected...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-06-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry